Innovative therapeutic vaccine  XEMYS™ for the treatment of multiple sclerosis

Innovative therapeutic vaccine XEMYS™ for the treatment of multiple sclerosis

Xemys™ — Specific Immunotherapy (SIT) for Multiple Sclerosis 

The existing methods of treating multiple sclerosis mostly systematically suppress the patient's immune system and make him more vulnerable to infections. It is expected that the new vaccine will be completely devoid of such undesirable effects.



Xemys™ 

— 

SPECIFIC IMMUNOTHERAPY (SIT) FOR MULTIPLE SCLEROSIS 

The existing methods of treating multiple sclerosis mostly systematically suppress the patient's immune system and make him more vulnerable to infections. It is expected that the new vaccine will be completely devoid of such undesirable effects.


XEMYS™ was created on the base of a number of fundamental discoveries related to how autoreactive lymphocytes (including B-cells) behave in the course of multiple sclerosis.

The mechanism of action of the drug consists of a biphasic Th1-Th2 shift and further induction of T-regulatory cells. The drug contains immunodominant peptides of basic myelin protein, encapsulated in small mannosylated liposomes, and has successfully passed two phases of clinical trials.

 

Liposomes are microparticles surrounded by a sheath of fat molecules that allow targeted delivery of myelin peptides to antigen-presenting cells for induction of immune system tolerance. 

XEMYS™ was created on the base of a number of fundamental discoveries related to how autoreactive lymphocytes (including B-cells) behave in the course of multiple sclerosis.

The mechanism of action of the drug consists of a biphasic Th1-Th2 shift and further induction of T-regulatory cells. The drug contains immunodominant peptides of basic myelin protein, encapsulated in small mannosylated liposomes, and has successfully passed two phases of clinical trials.

Liposomes are microparticles surrounded by a sheath of fat molecules that allow targeted delivery of myelin peptides to antigen-presenting cells for induction of immune system tolerance. 

STAGE OF DEVELOPMENT

THE BENEFITS OF XEMYS™

High specificity

Induction of tolerance to our own myelin antigens                                                                                                                                                            



Safety

Virtually no presence of side effects                                                                                                                                                                                                        


Effectiveness

Stabilization of the condition in patients with previously non-coupable    




Cost

It is expected, that XEMYS™ will be cheaper than existing drugs for multiple sclerosis therapy due to the perfection of its production technology



High specificity

Induction of tolerance to our own myelin antigens



Safety

Virtually no presence of side effects



Effectiveness

Stabilization of the condition in patients with previously non-coupable



Cost

It is expected, that XEMYS™ will be cheaper than existing drugs for multiple sclerosis therapy due to the perfection of its production technology





DEVELOPERS

Was created by scientists of the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences in cooperation with Pharmsynthez PJSC and Xenetic Biosciences, Inc.

The Shemyakin & Ovchinnikov Institute of bioorganic chemistry (IBCh) of the Russian Academy of Sciences is one of the largest Russian scientific organizations. The Institute is a leader in fundamental and innovative researches on the fields of molecular, structural and cell biology, bioorganic chemistry, biophysics, bioengineering, cell technologies, “in vivo” molecular based bioimaging, genome editing, bioinformatics etc. This multidisciplinary structure allows large-scale research at the interface of sciences, where the most interesting scientific discoveries are born today.

The hallmark of the IBCh RAS is the concentration of efforts and resources on solving the most urgent and complicated problems on the field of life sciences. Talented young people and leading specialists, including Russian and foreign science leaders, Nobel Prize laureates and members of the international advisory council of the Institute are involved in.


PUBLICATIONS


CONTACT us

get in touch

On cooperation issues please contact the head of NTI Center project department
Sergey Semenov

address 16/10, Miklukho-Maklaya St, Moscow, Russian Federation, 117997

All products and services of NTI Center IBHh RAS